ロード中...
Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why
It is well known that chemotherapy can cure only some cancers in advanced stage, mostly those with an intact p53 pathway. Hematological cancers such as lymphoma and certain forms of leukemia are paradigmatic examples of such scenario. Recent evidence indicates that the efficacy of many of the alkyla...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5984324/ https://ncbi.nlm.nih.gov/pubmed/29855342 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0609-1 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|